Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 12/20 | 0.53 |
| ▸ | MAOA | P21397 | 6/20 | 0.36 |
| ▸ | MAOB | P27338 | 6/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17332092 | 0.89 | GRM5 (0.47) | GRM5MAOAMAOBCYP2A6 | |
| SCHEMBL14979694 | 0.87 | GRM5 (0.47) | GRM5MAOAMAOBCYP2A6PRKCI | |
| SCHEMBL17332147 | 0.84 | GRM5 (0.44) | GRM5MAOAMAOBCYP2A6PRKCI | |
| SCHEMBL17332161 | 0.84 | GRM5 (0.44) | GRM5MAOAMAOBCYP2A6PRKCI | |
| SCHEMBL19566332 | 0.83 | GRM5 (0.49) | GRM5MAOAMAOBCYP2A6PRKCI | |
| SCHEMBL22992385 | 0.80 | GRM5 (0.46) | GRM5MAOAMAOBCYP2A6PRKCI | |
| SCHEMBL18634519 | 0.79 | GRM5 (0.45) | GRM5MAOAMAOBCYP2A6PRKCI | |
| SCHEMBL17332079 | 0.78 | GRM5 (0.44) | GRM5MAOAMAOBPRKCIBAZ2B | |
| SCHEMBL17332094 | 0.78 | GRM5 (0.45) | GRM5MAOAMAOBCYP2A6PRKCI | |
| SCHEMBL19548369 | 0.78 | MAOB (0.46) | GRM5MAOAMAOBCYP2A6PRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192875-B2 | Processes for preparing antiviral compounds | GILEAD PHARMASSET LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200392100-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2020-12-17 | — | — | US | disclosed |
| US-10584109-B2 | Processes for preparing antiviral compounds | Gillead Pharmasset LLC (US) | 2020-03-10 | — | — | US | disclosed |
| US-20190263771-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2019-08-29 | — | — | US | disclosed |
| US-20180179175-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2018-06-28 | — | — | US | disclosed |
| US-9890134-B2 | Processes for preparing antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170283390-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9670187-B2 | Processes for preparing antiviral compounds | GILEAD PHARMASSET LLC (US) | 2017-06-06 | — | — | US | disclosed |
| EP-3154984-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-20150361073-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-17 | — | — | US | disclosed |
| WO-2015191437-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10584109-B2 | Processes for preparing antiviral compounds | MAVS, EIF2AK2, SAMHD1 | GRM5 3842/4885MAOA 1588/4885MAOB 1117/4885 |
| US-11192875-B2 | Processes for preparing antiviral compounds | MAVS, EIF2AK2, SAMHD1 | GRM5 3842/4885MAOA 1588/4885MAOB 1117/4885 |
| US-20170283390-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SAMHD1 | GRM5 3842/4885MAOA 1588/4885MAOB 1117/4885 |
| US-20150361073-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SAMHD1 | GRM5 3842/4885MAOA 1588/4885MAOB 1117/4885 |
| US-20180179175-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SAMHD1 | GRM5 3842/4885MAOA 1588/4885MAOB 1117/4885 |
| US-20200392100-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SAMHD1 | GRM5 3842/4885MAOA 1588/4885MAOB 1117/4885 |
| US-20190263771-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SAMHD1 | GRM5 3842/4885MAOA 1588/4885MAOB 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.